Launch Tech Co Ltd Stock
Price
Target price
€0.80
€0.80
3.250%
0.025
3.250%
-
18.08.26 / Stuttgart Stock Exchange
WKN: A0M4VZ / Name: Launch / Stock / Machinery, Equipment & Components / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Launch Tech Co Ltd Stock
Launch Tech Co Ltd dominated the market today, gaining €0.025 (3.250%).
Pros and Cons of Launch Tech Co Ltd in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Launch Tech Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Launch Tech Co Ltd | 3.250% | -1.242% | 8.163% | -37.303% | -15.605% | 172.260% | 94.853% |
| Chongqing Machinery & Electric Co Ltd | -3.600% | -7.759% | 18.889% | 9.744% | 1.905% | 315.534% | 319.608% |
| Hurco Companies Inc | -1.020% | 1.042% | 2.646% | - | - | - | - |
| Tennant Co. | 0.590% | -2.831% | -22.148% | -16.643% | -8.110% | - | - |
News
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing
Applied Aerospace & Defense Q2 Earnings Call Highlights
Key Points
- Interested in Applied Aerospace & Defense, Inc.? Here are five stocks we like better.
- Record second-quarter results: Revenue rose 47.4% year over year to $167.3 million, while
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances
Key Points
- Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better.
- Compass Pathways expects to complete its FDA application for COMP360 in the fourth quarter of